ReviewThe Journal of infectious diseases2015
Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects.
Review in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Stool specimen for diagnosis of pulmonary tuberculosis in adults: a systematic review.BMJ open · 2023Pooled it
- Meta-Analysis and Data Mining-Based Study on the Expression Characteristics of Inflammatory Factors and Causes of Recurrence in Spinal Tuberculosis.Computational and mathematical methods in medicine · 2022Pooled it
- Delay in seeking care for tuberculosis symptoms among adults newly diagnosed with HIV in rural Malawi.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2018Trial
- Trial
- Exploring tuberculosis physicians' preferences for AI explainability in China: a protocol for a discrete choice experiment.BMJ open · 2026Article
- Article
- ASAP1 as a novel dual-level biomarker for tuberculosis: integrated genetic and proteomic evidence for early detection and disease monitoring.Molecular biology reports · 2026Article
- Article
- Smart photonic crystal fiber optical sensor for tuberculosis detection with machine learning integration.Scientific reports · 2025Article
- Diagnostic Modality Influences Tuberculosis Detection in People Living with HIV: Eight Years of Data from a Thai Referral Center.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Article
- [Application Of Next Generation Sequencing To Diagnosis OfTap chi y hoc du phong = Journal of preventive medicine · 2024Article
- Performance evaluation of Truenat MTB and Truenat MTB-RIF DX assays in comparison to gene XPERT MTB/RIF ultra for the diagnosis of pulmonary tuberculosis in Uganda.BMC infectious diseases · 2024Article
- Identification ofInfection and drug resistance · 2024Review
- Sensitive Blood-Based Detection of HIV-1 and Mycobacterium tuberculosis Peptides for Disease Diagnosis by Immuno-Affinity Liquid Chromatography-Tandem Mass Spectrometry: A Method Development and Proof-of-Concept Study.Clinical chemistry · 2023Article
- Updating the WHO target product profile for next-generation Mycobacterium tuberculosis drug susceptibility testing at peripheral centres.PLOS global public health · 2023Article
- A CRISPR-Cas12a-based platform for ultrasensitive rapid highly specific detection ofFrontiers in cellular and infection microbiology · 2023Article
- Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing.PloS one · 2023Article
- Diagnostic Accuracy of the Truenat MTB Plus Assay and Comparison with the Xpert MTB/RIF Assay to Detect Tuberculosis among Hospital Outpatients in Cameroon.Journal of clinical microbiology · 2022Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In 2015, tuberculosis remains a major global health problem, and drug-resistant tuberculosis is a growing threat. Although tuberculosis diagnosis in many countries is still reliant on older tools, new diagnostics are changing the landscape. Stimulated, in part, by the success and roll out of Xpert MTB/RIF, there is now considerable interest in new technologies. The landscape looks promising, with a robust pipeline of new tools, particularly molecular diagnostics, and well over 50 companies actively engaged in product development. However, new diagnostics are yet to reach scale, and there needs to be greater convergence between diagnostics development and development of shorter-duration tuberculosis drug regimens. Another concern is the relative absence of non-sputum-based diagnostics in the pipeline for children and of biomarker tests for triage, cure, and progression of latent Mycobacterium tuberculosis infection. Several initiatives, described in this supplement, have been launched to further stimulate product development and policy, including assessment of needs and priorities, development of target product profiles, compilation of data on resistance-associated mutations, and assessment of market size and potential for new diagnostics. Advocacy is needed to increase funding for tuberculosis research and development, and governments in high-burden countries must invest more in tuberculosis control to meet post-2015 targets for care, control, and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.